Developing Recombinant Anti-Idiotypic Antibodies for PK/PD and Immunogenicity Assays
1,270 views
|
February 20, 2017
"For more information, visit http://www.bio-rad.com/yt/1/AbD-Serotec Dr Achim Knappik of AbD Serotec describes the use of recombinant anti-idiotypic antibodies as specialized tools in the development of preclinical and clinical research assays for antibody drug development and how they are generated using proprietary HuCAL® recombinant antibody generation technology. Dr Knappik is the main inventor of the HuCAL technology. He defines and illustrates the types of anti-drug antibodies and their applications in determining the levels of therapeutic antibody drugs in serum and the detection of patient immune response to the drug. The HuCAL PLATINUM® antibody library, containing ~45 billion members, is used with a guided selection method to generate high-affinity, anti-idiotypic antibodies (as Fabs) in just eight weeks; these monoclonal anti-idiotypic antibodies can be generated in large quantities with great consistency, and they can be further engineered to allow various assay designs. The presentation concludes with a case study of the development of anti-trastuzumab (Herceptin®) antibodies and highlights a few of the company's anti-idiotypic antibody products. Presenter: Dr Achim Knappik Head of Research and Development at AbD Serotec, a Bio-Rad company AbD Serotec offers both an extensive range of primary and secondary antibodies and reagents as well as custom antibody generation services including anti-idiotypic antibodies. http://www.abdserotec.com/hucal-anti-drug-antibodies.html?WT.mc_id=yt-lsr-ww-abdserotec-20131203-ATgltK-dTVM HuCAL® and HuCAL PLATINUM® are registered trademarks of MorphoSys AG. Herceptin® is a registered trademark of Genentech Inc. USA."
Immunology
